Chromocell is a biotechnology company focused on developing innovative, non-addictive drugs for the treatment of chronic neuropathic pain and acute to chronic eye pain. Committed to breakthroughs in pain management, Chromocell aims to provide effective alternatives that address the global challenges of pain and addiction.
Specialties
Non-addictive pain management
Chronic neuropathic pain treatment
Acute and chronic eye pain solutions
NaV1.7 inhibitor innovation
Biotechnology development
Products & Services
Non-addictive pain medications
Chronic neuropathic pain treatments
Acute eye pain therapies
Chronic eye pain solutions
Pain management alternatives
Contact Information
No contact information available
Competitors & Similar Companies(7)
AcelRx Pharmaceuticals
California, • United States
Aoxing Pharmaceutical Company
Sorrento Therapeutics
California, • United States
Inovio Pharmaceuticals
Pennsylvania, • United States
NeurogesX
California, • United States
Revance Therapeutics
California, • United States
Celsius Therapeutics
News & Media
Search Terms:
chromocell therapeuticschromocell
Search Topics:
AcquisitionAI: Product LaunchInvestment: Approval FundingProject: Bid and AuctionBusiness ExpansionFinancing and FundraisingInvestmentJoint VentureLeadership Change (CXO)MergerPartnershipProduct LaunchPublic Offering (IPO)RebrandingReorganizationRestructuringValuation
Loading...
Frequently Asked Questions about Chromocell
Where is Chromocell located?
The headquarter of Chromocell is located in North Brunswick, New Jersey, United States
Competitors of Chromocell are AcelRx Pharmaceuticals, Aoxing Pharmaceutical Company, Sorrento Therapeutics, Inovio Pharmaceuticals, NeurogesX, Revance Therapeutics, Celsius Therapeutics.
What does Chromocell do?
Chromocell is a biotechnology company focused on developing innovative, non-addictive drugs for the treatment of chronic neuropathic pain and acute to chronic eye pain. Committed to breakthroughs in pain management, Chromocell aims to provide effective alternatives that address the global challenges of pain and addiction.